BioNexus Gene Lab Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $3.1M-67.1% YoYTTM through 30 Jun 2026
Net Income -$2.6MTTM through 30 Jun 2026
Free Cash Flow -$853.6KTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 14.7% |
| EBITDA Margin | -80.5% |
| Operating Margin | -40.0% |
| Net Margin | -82.4% |
Returns
-36.8%ROE
-33.0%ROA
Balance Sheet Health
Debt / Equity0.02x
Current Ratio6.08x
Net Debt-$3.8Mnet cash position
Cash & Equivalents$1.2M
Quality Metrics
Altman Z-Score1.51
Piotroski F-Score2 / 9
FCF Margin-27.3%
Multi-Year Trend
RevenueFY2025: $7.4M
Diluted EPSFY2024: $-0.09
Dividend
No dividend
Capital Allocation
R&D Spend$54.1K
Capex Intensity0.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Chemrex Corporation Sdn. Bhd. (Chemical Raw Materials) | View detailsRepositioning from chemical trading toward a phased CDMO model focused on biotech and high-tech manufacturing. | ||
| MRNA Scientific Sdn. Bhd. (Genomic Screening) | View detailsPivoting toward the commercial rollout of the VitaGuard MRD platform across Southeast Asia starting in 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.